Guidance
← 실적 발표
01
02
03
04 05 06
톤
AI
자본지출
A1 A2
PFE
FY2026 Q2
상향
Pfizer, Inc. 실적 발표
Buzzberg 분석
Company raises revenue guidance despite lower COVID revenues
Pfizer raised FY2026 revenue guidance on strong non-COVID execution while maintaining EPS guidance despite a $500M COVID revenue cut. Management highlighted pipeline progress in oncology and obesity, including new pivotal trials for its bispecific antibody. FY2026 revenue guidance raised by $0.5B to $60.5-62.5B, offset by a $1.0B cut in COVID revenue expectations.
Buzzberg 분석 Company raises revenue guidance despite lower COVID revenues Pfizer raised FY2026 revenue guidance on strong non-COVID execution while maintaining EPS guidance despite a $500M COVID revenue cut. Management highlighted pipeline progress in oncology and obesity, including new pivotal trials for its bispecific antibody. FY2026 revenue guidance raised by $0.5B to $60.5-62.5B, offset by a $1.0B cut in COVID revenue expectations. 전체 분석 보기분석 접기
Pfizer raised FY2026 revenue guidance on strong non-COVID execution while maintaining EPS guidance despite a $500M COVID revenue cut. Management highlighted pipeline progress in oncology and obesity, including new pivotal trials for its bispecific antibody. FY2026 revenue guidance raised by $0.5B to $60.5-62.5B, offset by a $1.0B cut in COVID revenue expectations.
- Non-COVID business delivered 5% operational revenue growth in Q2; acquired products grew 27% operationally.
- Initiated Phase 3 trials for its bispecific antibody, including a head-to-head vs. Dupixent powered for superiority.
- Updated Phase 1 data in 1L NSCLC shows ~82% ORR for its ADC+anti-PD-1 combo, supporting its Phase 3 program.
매출$15.034B+4% 전분기 대비
주당순이익(EPS)$0.77+3% 전분기 대비
매출총이익률72.78%보고값
영업이익률31.3%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Growth
Acquired product revenues grew 27% operationally, excluding one-time items
Costs
Additional $2.5 billion net cost savings expected from 2027-2029
핵심 내용 3개 더 보기
Capital Allocation
Dividend to be maintained and eventually grow
Pipeline
Vera binitide shows potential for monthly obesity therapy with comparable efficacy
Pipeline
Telrecamig to be tested head-to-head against Dupixent in atopic dermatitis
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $15.034B | +4% 전분기 대비 |
| 주당순이익(EPS) | $0.77 | +3% 전분기 대비 |
| 매출총이익률 | 72.78% | 보고값 |
| 영업이익률 | 31.3% | 보고값 |
| 잉여현금흐름 | $0.302B | 보고값 |
| 자본지출 | $0.533B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 주당순이익(EPS) | FY2026 | $2.80–$3.00 | $2.90 | 유지 |
| 매출 | FY2026 | $60.5B–$62.5B | $61.5B | 상향 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management repeatedly highlighted strong execution, raised revenue guidance, and expressed confidence in future growth and dividend maintenance, despite acknowledging challenges like COVID revenue declines and pipeline setbacks.
경영진의 AI 분석
Management views AI as a structural transformation opportunity, already seeing benefits in manufacturing cost reduction, yield expansion, commercial field force effectiveness, and marketing approaches, with ambitions to build an AI-native R&D organization.
투자 및 생산능력
Pfizer is expanding its manufacturing optimization program, expecting total net cost savings of approximately $3 billion through 2029, with additional savings from the next phase focused on network structure changes, product portfolio enhancement, and operational efficiency.
아래에 언급된 기업 8개 모두 표시
기업발표 이후 수익률
파트너
파트너
Cécile Guégan
Pfizer acknowledges BMS's public guidance on Eliquis growth as a key driver for its own raised revenue guidance.
근거
“with a driver that our partner BMS has described”
파트너
Chris Boshoff
Pfizer highlights the scale of development for the in-licensed bispecific, signaling activity and progress on the asset.
근거
“Since in-licensing from 3SV about a year ago, we started nine trials including two Phase III studies”
경쟁사
경쟁사
Chris Boshoff
Pfizer's model projects its candidate as potentially superior to Novo's semaglutide in weight loss, a direct competitive claim.
근거
“the analysis suggests barabenotype can deliver weight loss comparable to desepatite and potentially better than semaglutide.”
경쟁사
Chris Boshoff
Pfizer highlights its bispecific's Phase 2 data against Regeneron's ivonescimab, suggesting a potential competitive advantage.
근거
“these data compare favorably with Ivernissimab Phase III results in this population”
경쟁사
Chris Boshoff
Pfizer references Merck's pembrolizumab as a benchmark for combination opportunity, emphasizing the clinical utility of the regimen.
근거
“These data align with the ability of the DOTIN ADCs to induce immunogenic cell death and thereby potentially synergize with anti-PD-1 agents such as pembrolizumab.”
경쟁사
Chris Boshoff
Pfizer reports a Phase 1/2 trial design for its once-monthly GLP-1 and amylin combination is focused on tolerability, positioning it as a potential differentiated therapy. — A tolerable monthly combination could provide a significant convenience advantage over weekly rivals like Lilly's Zepbound.
근거
“it is encouraging that berubenatide achieved week 28 efficacy that was similar to tesepatite's medium dose of 10 mg in the SUMMOUND-1 study”
공급망
공급망
Chris Boshoff
Pfizer plans to start a Phase 3 trial for a bispecific antibody directly vs. Dupixent, powered for superiority, in a head-to-head setting. — A potential weekly alternative to Dupixent could challenge Sanofi's franchise in atopic dermatitis and asthma.
근거
“Indeed, this will be one of the first phase three trials that will be head against DUPI and powered for superiority against DUPI.”
외부 신호
공급망 알파 · 2발표 이후 수익률
Pfizer plans to start a Phase 3 trial for a bispecific antibody directly vs. Dupixent, powered for superiority, in a head-to-head setting.
Pfizer reports a Phase 1/2 trial design for its once-monthly GLP-1 and amylin combination is focused on tolerability, positioning it as a potential differentiated therapy.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 8개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.